Right-to-Try or Right-to-Ask? Understanding Right-to-Try and FDA’s Expanded Access
Right-to-Try has been in the news a lot recently, but what does it actually mean for product sponsors? This webinar explores both Right-to-Try legislation and existing Expanded Access Programs, including:
Understanding sponsor responsibilities under these programs and when products may be eligible for these programs
Evaluating options such as treatment protocols, treatment INDs, and emergency use
Discussing development risks associated with participation in these programs
The presenters will also provide several examples from both their personal experience as well as noteworthy examples that have made the news.